Investigational drug · Phase 3
matched to Pregabalin
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Diabetic Peripheral Neuropathic Pain.
Phase 3Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
41
Any phase or sponsor naming "matched to Pregabalin"
First trial start
2024
Oct 1, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "matched to Pregabalin", any sponsor or status.
- Phase 214
Conditions studied
As listed on its trial records.
- Diabetic Peripheral Neuropathic Pain
Approved drugs for the same conditions: Neuropathic pain · Cardiovascular and metabolic · Neurology · Pain and anesthesia
Largest trials
Live from ClinicalTrials.gov: studies naming "matched to Pregabalin" as an intervention, largest first.
- Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral NeuropathyPivotal-lookingRecruiting
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT06628908 · 1,100 participants (planned) · Start Oct 1, 2024 · Primary completion May 31, 2027
Drug: Suzetrigine; Placebo (matched to SUZ) and 2 more · For: Diabetic Peripheral Neuropathic Pain
Sites: Anniston, Alabama; Birmingham, Alabama; Daphne, Alabama · 76 sites in all
- Cebranopadol Efficacy and Safety in Diabetic Patients Suffering From Chronic Pain Caused by Damage to the NervesPivotal-lookingCompleted
Tris Pharma, Inc.Industry
NCT01939366 · 699 participants · Start Sep 27, 2013 · Primary completion Jan 2015
Drug: Cebranopadol 100 µg; Cebranopadol 300 µg and 3 more · For: Chronic Pain; Diabetic Neuropathies; Diabetes Mellitus
Sites: Mesa, Arizona; Garden Grove, California; Laguna Hills, California · 82 sites in all
- Study To Evaluate Efficacy, Safety And Tolerability Of Lyrica In Patients With Painful Diabetic Peripheral NeuropathyPivotal-lookingCompleted
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
NCT01332149 · 626 participants · Start Jul 2011 · Primary completion Apr 2014
Drug: Pregabalin; Placebo matched with pregabalin · For: Diabetic Neuropathy, Painful
Sites: Chongqing, China; Fuzhou, China; Guangzhou, China · 30 sites in all
- Study Of The Efficacy And Safety Of Pregabalin Compared To Placebo For Treatment Of Post-Surgical Pain From HysterectomyPivotal-lookingCompleted
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
NCT00468845 · 501 participants · Start Jun 2007 · Primary completion May 2010
Drug: pregabalin (Lyrica); pregabalin (Lyrica) and 1 more · For: Pain, Postoperative
Sites: Mobile, Alabama; Glendale, Arizona; Phoenix, Arizona · 42 sites in all
- Once-A-Day Pregabalin For Partial SeizuresPivotal-lookingCompleted
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
NCT01262677 · 325 participants · Start Feb 17, 2011 · Primary completion Jul 31, 2012
Drug: pregabalin; pregabalin and 5 more · For: Partial Seizures; Epilepsies, Partial
Sites: Northport, Alabama; Jonesboro, Arkansas; Little Rock, Arkansas · 82 sites in all
- Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral NeuropathyPivotal-lookingRecruiting
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT06619860 · 300 participants (planned) · Start Oct 18, 2024 · Primary completion Mar 25, 2027
Drug: VX-993; Pregabalin and 2 more · For: Diabetic Peripheral Neuropathic Pain
Sites: Cullman, Alabama; Bakersfield, California; La Mesa, California · 47 sites in all
Kaohsiung Medical University Chung-Ho Memorial HospitalAcademic, hospital or other
NCT04832100 · 245 participants (planned) · Start Jun 1, 2021 · Primary completion Jun 30, 2026
Drug: Pregabalin 150mg, imipramine 25mg · For: Fibromyalgia, Primary; Pain; Soreness, Muscle and 3 more
Sites: Kaohsiung City, Taiwan
- Evaluate the Efficacy and Safety of JMKX000623 in Participants With Diabetic Peripheral Neuropathic PainPivotal-lookingStatus unknown
JemincareIndustry
NCT06221241 · 220 participants (planned) · Start Mar 25, 2024 · Primary completion Mar 14, 2025
Drug: JMKX000623; Pregabalin and 1 more · For: Diabetic Peripheral Neuropathic Pain
Sites: Beijing, China
- A 17-Week Trial To Assess Pregabalin For The Treatment Of Nerve Pain Due To Spinal Cord InjuryPivotal-lookingCompleted
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
NCT00407745 · 220 participants · Start Jan 2007 · Primary completion Feb 2011
Drug: placebo; pregabalin · For: Neuralgia; Spinal Cord Injuries
Sites: Phoenix, Arizona; Fresno, California; Napa, California · 67 sites in all
- Efficacy Of Pregabalin In Subjects With Post-Stroke Central Neuropathic PainPivotal-lookingCompleted
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
NCT00313820 · 220 participants · Start Aug 2006 · Primary completion Sep 2008
Drug: Pregabalin; Placebo · For: Central Neuropathic Pain
Sites: Darlinghurst, Australia; East Gosford, Australia; St Leonards, Australia · 33 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Diabetic Peripheral Neuropathic Pain
- HL-1186Phase 36 trials
Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. · Postoperative Pain, Moderate to Severe Acute Postoperative Pain, Postherpetic Neuralgia ( PHN )
- matched to SUZPhase 32 trials
Vertex Pharmaceuticals · Diabetic Peripheral Neuropathic Pain
- LY4065967Phase 23 trials
Eli Lilly · Chronic Pain, Diabetic Peripheral Neuropathic Pain, Osteoarthritis, Knee
- matched to VX-993Phase 22 trials
Vertex Pharmaceuticals · Diabetic Peripheral Neuropathic Pain, Acute Pain
- VX-993Phase 22 trials
Vertex Pharmaceuticals · Diabetic Peripheral Neuropathic Pain, Acute Pain
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Vertex Pharmaceuticals.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.